Delusional Disorder, Schizoaffective Disorder, Schizophrenia
Conditions
Keywords
schizophrenia, psychosis, type 2 diabetes mellitus
Brief summary
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls. Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
Detailed description
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls. Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.
Interventions
None listed
Sponsors
American Association for Geriatric Psychiatry
Janssen Pharmaceuticals
University of Pittsburgh
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association
Exclusion criteria
* Diabetes, type 1 or 2 * Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use) * Age above 50 or age below 14
Countries
United States
Outcome results
None listed